15 Jan SynGenSys
David James, Ph.D., Chief Scientific Officer
April 29 | 4:30pm | Salone dei Cavalieri, Section 1
Sheffield, United Kingdom
(Private)
SynGenSys designs synthetic promoter systems and signal peptides to enable precise control of gene expression for cell and gene therapy applications and biopharmaceutical manufacturing. Using its proprietary bioinformatics platform and integrated testing workflows, SynGenSys develops compact, tunable promoters that deliver tissue-specific targeting and accurate dosing for DNA-based gene therapies and gene-modified cell therapies including CAR-T and CAR-NK. Promoter systems are independent of delivery vector , improving targeting for viral vectors such as AAV and non-viral approaches. SynGenSys’s signal peptides are engineered to optimize protein translocation and expression for secreted and membrane-anchored transgenes such as CARs and clotting factor VIII. SynGenSys also supports biopharmaceutical manufacturing with off-the-shelf and custom promoter systems that improve yield and turnaround time, even for multi- component or difficult-to-express proteins. By combining computational transcriptional analysis with rational design, SynGenSys delivers promoter and signal peptide solutions that enhance safety, efficacy, and manufacturability for next-generation medicines.
